MONICA SAM: Open Payments
NPI 1184115354 · WILMINGTON, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,504 in 18 payments from 12 companies in 2025. Trend: 2023 $1,113 · 2024 $838 · 2025 $1,504
Food & beverage: $1,504
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 2 | $237 |
| Axsome Therapeutics, Inc. | 2 | $201 |
| Neurocrine BioSciences, Inc. | 1 | $133 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $126 |
| Janssen Pharmaceuticals, Inc | 2 | $124 |
| Verona Pharma, Inc. | 1 | $124 |
| United Therapeutics Corporation | 2 | $120 |
| Otsuka America Pharmaceutical, Inc. | 3 | $114 |
| Abbott Laboratories | 1 | $97 |
| Braeburn Inc. | 1 | $92 |
Products named: FANAPT, Auvelity, INGREZZA, CAPLYTA, INVEGA SUSTENNA, Ohtuvayre, TYVASO, REXULTI.
Industry payments across DE — which companies pay providers there.
